Market Research Report
Global Pharmacogenomics Market, by Technology Type, Application and Geography - Trends and Forecast to 2025
|Published by||Coherent Market Insights||Product code||593069|
|Published||Content info||210 Pages
Delivery time: 2-3 business days
|Global Pharmacogenomics Market, by Technology Type, Application and Geography - Trends and Forecast to 2025|
|Published: November 22, 2017||Content info: 210 Pages||
Pharmacogenomics is an essential research area for development of medication for pain, cancer, psychotropic, and cardiovascular disease. The success of this medication is possible through the use of innovative technologies that help define the dosage setting for subsets of the population and an individual’s response to a specific drug. The success of the precision medicine is possible through the application of pharmacogenomics that uses information about a person’s genes, enzyme activities, cellular environment, and proteins to diagnose and treat diseases. Rapid advancements in groups of specialized molecular diagnostic tests is contributing to the improvement for assessment of real-time treatment of diseases.
Major factors that propel the market are increasing demand for personalized drugs, increasing prevalence of several non-infectious and infectious diseases, rising utilization of these technology for effective treatment therapeutics, and growing awareness about benefits associated with pharmacogenomics. Continuous collaboration among pharmacogenomics manufacturers for various applications in clinical and translational research is also expected to drive growth of the market across regions. In 2016, Merck & Co. Inc., collaborated with Biocartis, an innovative molecular diagnostic company to develop and commercialize a new liquid biopsy technology for RAS biomarker testing. This can enable more access to the test for number of metastatic colorectal cancer patients. Furthermore, use of pharmacogenomics to perform diagnostic assays in the field of determining individual’s susceptibility to certain diseases, toxicology, biochemical genetics, and drug safety are also expected to lead to rapid growth of the market for pharmacogenomics over the forecast period.
This report provides in-depth analysis of pharmacogenomics and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, regulatory scenario, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global pharmacogenomics market based on the following parameters – company overview, financial performance, geographical presence, key developments and strategies, and future plans
Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Bayer AG, AstraZeneca plc, Assurex Health, GE Healthcare, Bristol-Myers Squibb Company, Qiagen, Inc., F. Hoffmann-La Roche Ltd, Transgenomic, Inc., Abbott Laboratories, Inc., and GlaxoSmithKline
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future type up-gradation, market expansion, and marketing tactics
The global pharmacogenomics market report caters to various stakeholders in this industry including investors, researchers, pharmacogenomics manufacturers, new entrants, and financial analysts.
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the pharmacogenomics market.